Compounds > sdz mrl 953

Page last updated: 2024-12-08

sdz mrl 953

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

SDZ MRL 953: monosaccharide lipid A analog which has improved activity in experimental sepsis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	164140
SCHEMBL ID	9324214
MeSH ID	M0188423

Synonyms (11)

Synonym
sdz mrl 953
[(2r,3s,4r,5r,6r)-2-(hydroxymethyl)-5-[[(3r)-3-oxidanyltetradecanoyl]amino]-4-[(3r)-3-oxidanyltetradecanoyl]oxy-6-phosphonooxy-oxan-3-yl] (3r)-3-oxidanyltetradecanoate
A808289
(3r)-3-hydroxytetradecanoic acid [(2r,3s,4r,5r,6r)-2-(hydroxymethyl)-4-[(3r)-3-hydroxy-1-oxotetradecoxy]-5-[[(3r)-3-hydroxy-1-oxotetradecyl]amino]-6-phosphonooxy-3-oxanyl] ester
[(2r,3s,4r,5r,6r)-2-(hydroxymethyl)-5-[[(3r)-3-hydroxytetradecanoyl]amino]-4-[(3r)-3-hydroxytetradecanoyl]oxy-6-phosphonooxyoxan-3-yl] (3r)-3-hydroxytetradecanoate
alpha-d-glucopyranose, 2-deoxy-2-((3-hydroxy-1-oxotetradecyl)amino)-, 1-(dihydrogen phosphate) 3,4-bis(3-hydroxytetradecanoate), (2(r),3(r),4(r))-
sdz mrl-953
2-deoxy-3,4-bis-o-(3-hydroxytetradecanoyl)-2-(3-hydroxytetradecanoylamido)-1-o-phosphono-alpha-d-glucopyranose
123136-61-8
SCHEMBL9324214
DTXSID70153870

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" Hence, repeated dosing with the compound induced a transient resistance (greater than or equal to 1 week) to lethal challenges with endotoxin."	( SDZ MRL 953, a novel immunostimulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis. Aschauer, H; Hildebrandt, J; Lam, C; Liehl, E; Macher, I; Schütze, E; Stütz, P, 1991)	1.72

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	8 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (12.50%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (87.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	1.97	1	0
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	1.98	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
galactosamine 2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.	2.38	2	0	D-galactosamine; primary amino compound	toxin
phosphotyrosine Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.. O(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group.	1.98	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid; O(4)-phosphotyrosine	Escherichia coli metabolite; immunogen
lipid x lipid X: monosaccharide precursor of E coli lipid A; structure given in first source; see also lipid A precursors, Salmonella. lipid X : An N-acyl-D-glucosamine 1-phosphate where the N-acyl group is (R)-3-hydroxytetradecanoyl and carrying an additional (R)-3-hydroxytetradecanoyl group at the 3-position.	1.98	1	0	N-acyl-D-glucosamine 1-phosphate	Escherichia coli metabolite
sdz 880-431 SDZ 880-431: structure given in first source; inhibits the action of lipopolysaccharides on neutrophils	1.98	1	0
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	1.98	1	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	1.97	1	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
lipid a Lipid A: Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.. lipid A : The glycolipid moiety of bacterial lipopolysaccharide (R can be either hydrogen or a fatty acyl group).	4.87	8	1	dodecanoate ester; lipid A; tetradecanoate ester	Escherichia coli metabolite
glycolipids [no description available]	1.98	1	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	3.78	2	1
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	1.98	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Blood Poisoning [description not available]	0	2.39	2	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	0	2.39	2	0
Endotoxin Shock [description not available]	0	1.98	1	0
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	1.98	1	0
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	0	1.98	1	0
Acute Respiratory Distress Syndrome [description not available]	0	1.98	1	0
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	0	1.98	1	0
Benign Neoplasms [description not available]	0	3.38	1	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	3.38	1	1
Bacterial Disease [description not available]	0	1.97	1	0
Bacterial Infections Infections by bacteria, general or unspecified.	0	1.97	1	0
E coli Infections [description not available]	0	1.97	1	0
Infections, Staphylococcal [description not available]	0	1.97	1	0
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	0	1.97	1	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	0	1.97	1	0